Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines

Neoplasia

Volumn 11, Issue 10, 2009, Pages 1003-1011

  Neuwelt, Alexander J ^a,b   Wu, Y Jeffrey ^a   Knap, Narcyz ^b   Losin, Marcin ^b   Neuwelt, Edward A ^a,c,d   Pagel, Michael A ^a   Warmann, Steven ^e   Fuchs, Joerg ^e   Czauderna, Piotr ^b   Wozniak, Michal ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CISPLATIN; CYTOCHROME P450 2E1; GLUTATHIONE; PARACETAMOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN LEVEL; CANCER CELL CULTURE; CELL LEVEL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER LEVEL; LIVER TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 70149105274     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.09688     Document Type: Article

References (38)

1. Roebuck DJ and Perilongo G (2006). Hepatoblastoma: an oncological review. Pediatr Radiol 36, 183-186.
2. Malogolowkin MH, Katzenstein HM, Krailo M, Chen Z, Quinn JJ, Reynolds M, and Ortega JA (2008). Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. J Clin Oncol 26, 2379-2383.
3. Perilongo G, Shafford E, Maibach R, Aronson D, Brugieres L, Brock P, Childs M, Czauderna P, MacKinlay G, Otte JB, et al. (2004). Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology - SIOPEL 2. Eur J Cancer 40, 411-421. (Pubitemid 38121279)
4. Roebuck DJ, Aronson D, Clapuyt P, Czauderna P, de Ville de Goyet J, Gauthier F, Mackinlay G,Maibach R,McHugh K, Olsen OE, et al. (2007). 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol 37, 123-132; quiz 249-1150 (Pubitemid 46092102)
5. Yang C, Kaushal V, Shah SV, and Kaushal GP (2008). Autophagy is associated with apoptosis in cisplatin injury to renal tubular epithelial cells. Am J Physiol Renal Physiol 294, F777-F787.
6. Kartalou Mand Essigmann JM(2001). Recognition of cisplatin adducts by cellular proteins. Mutat Res 478, 1-21.
7. Meijer C, Mulder NH, Hospers GA, Uges DR, and de Vries EG (1990). The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line. Br J Cancer 62, 72-77. (Pubitemid 20226449)
8. Nakagawa K, Yokota J, Wada M, Sasaki Y, Fujiwara Y, Sakai M, Muramatsu M, Terasaki T, Tsunokawa Y,Terada M, et al. (1988). Levels of glutathione S transferase pi mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin. Jpn J Cancer Res 79, 301-304. (Pubitemid 18106765)
9. Hospers GA, Mulder NH, de Jong B, de Ley L, Uges DR, Fichtinger-Schepman AM, Scheper RJ, and de Vries EG (1988). Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis- diamminedichloroplatinum (II) in vitro. Cancer Res 48, 6803-6807. (Pubitemid 19012209)
10. Estabrook RW (2003). A passion for P450s (remembrances of the early history of research on cytochrome P450). Drug Metab Dispos 31, 1461-1473.
11. Kon K, Ikejima K, Okumura K, Aoyama T, Arai K, Takei Y, Lemasters JJ, and Sato N (2007). Role of apoptosis in acetaminophen hepatotoxicity. J Gastroenterol Hepatol 22 (Suppl 1), S49-S52.
12. Manov I, Hirsh M, and Iancu TC (2004). N-acetylcysteine does not protect HepG2 cells against acetaminophen-induced apoptosis. Basic Clin Pharmacol Toxicol 94, 213-225. (Pubitemid 38667867)
13. Wan J, Bae MA, and Song BJ (2004). Acetoaminophen-induced accumulation of 8-oxodeoxyguanosine through reduction of Ogg1 DNA repair enzyme in C6 glioma cells. Exp Mol Med 36, 71-77. (Pubitemid 38374727)
14. JaeschkeHand BajtML (2006). Intracellular signalingmechanisms of acetaminopheninduced liver cell death. Toxicol Sci 89, 31-41. (Pubitemid 43013752)
15. Posadas I, Vellecco V, Santos P, Prieto-Lloret J, and Cena V (2007). Acetaminophen potentiates staurosporine-induced death in a human neuroblastoma cell line. Br J Pharmacol 150, 577-585. (Pubitemid 46355549)
16. Wolchok JD, Williams L, Pinto JT, Fleisher M, Krown SE, Hwu WJ, Livingston PO, Chang C, and Chapman PB (2003). Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma. Melanoma Res 13, 189-196. (Pubitemid 36583983)
17. Heard KJ (2008). Acetylcysteine for acetaminophen poisoning. N Engl J Med 359, 285-292.
18. Dickey DT, Wu YJ, Muldoon LL, and Neuwelt EA (2005). Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 314, 1052-1058.
19. Dickey DT, Muldoon LL, Doolittle ND, Peterson DR, Kraemer DF, and Neuwelt EA (2008). Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models. Cancer Chemother Pharmacol 62, 235-241.
20. ZhengQY, Johnson KR, and Erway LC (1999). Assessment of hearing in 80 inbred strains of mice by ABR threshold analyses. Hear Res 130, 94-107.
21. Safirstein R, Andrade L, and Vieira JM (2000). Acetylcysteine and nephrotoxic effects of radiographic contrast agents - a new use for an old drug. N Engl J Med 343, 210-212. (Pubitemid 30489222)
22. Jarvinen K, Pietarinen-Runtti P, Linnainmaa K, Raivio KO, Krejsa CM, Kavanagh T, and Kinnula VL (2000). Antioxidant defense mechanisms of human mesothelioma and lung adenocarcinoma cells. Am J Physiol Lung Cell Mol Physiol 278, L696-L702. (Pubitemid 30220030)
23. Neuwelt EA, PagelMA, Kraemer DF, Peterson DR, andMuldoon LL (2004). Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther 309, 594-599.
24. Kobrinsky NL, Sjolander DE, Goldenberg JA, and Ortmeier TC (2005). Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-Wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue. Pediatr Blood Cancer 45, 222-225.
25. Wu YJ, Muldoon LL, and Neuwelt EA (2005). The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 312, 424-431.
26. Plate AY, Crankshaw DL, and Gallaher DD (2005). The effect of anesthesia by diethyl ether or isoflurane on activity of cytochrome P450 2E1 and P450 reductases in rat liver. Anesth Analg 101, 1063-1064; table of contents.
27. Casper D, Lekhraj R, Yaparpalvi US, Pidel A, JaggernauthWA,Werner P, Tribius S, Rowe JD, and LaSala PA (2000). Acetaminophen selectively reduces glioma cell growth and increases radiosensitivity in culture. J Neurooncol 46, 215-229. (Pubitemid 30410151)
28. Bae MA, Pie JE, and Song BJ (2001). Acetaminophen induces apoptosis of C6 glioma cells by activating the c-Jun NH(2)-terminal protein kinase-related cell death pathway. Mol Pharmacol 60, 847-856.
29. Harnagea-Theophilus E, Gadd SL, Knight-Trent AH, DeGeorge GL, and Miller MR (1999). Acetaminophen-induced proliferation of breast cancer cells involves estrogen receptors. Toxicol Appl Pharmacol 155, 273-279. (Pubitemid 29153375)
30. Gadd SL, Hobbs G, and Miller MR (2002). Acetaminophen-induced proliferation of estrogen-responsive breast cancer cells is associated with increases in c-myc RNA expression and NF-kappaB activity. Toxicol Sci 66, 233-243. (Pubitemid 34285118)
31. Manov I, Bashenko Y, Eliaz-Wolkowicz A, Mizrahi M, Liran O, and Iancu TC (2007). High-dose acetaminophen inhibits the lethal effect of doxorubicin in HepG2 cells: the role of P-glycoprotein and mitogen-activated protein kinase p44/42 pathway. J Pharmacol Exp Ther 322, 1013-1022. (Pubitemid 47295792)
32. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, and Spitz DR (2007). 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 67, 3364-3370.
33. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, and Anderson ME (1992). High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89, 3070-3074.
34. Bajt ML, Knight TR, Lemasters JJ, and Jaeschke H (2004). Acetaminopheninduced oxidant stress and cell injury in cultured mouse hepatocytes: protection by N-acetyl cysteine. Toxicol Sci 80, 343-349.
35. Harned TM, Kalous O, Neuwelt A, Loera J, Ji L, Iovine P, Sposto R, Neuwelt EA, and Reynolds CP (2008). Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. Clin Cancer Res 14, 533-540. (Pubitemid 351226123)
36. Kobrinsky NL, Hartfield D, Horner H, Maksymiuk A, Minuk GY, White DF, and Feldstein TJ (1996). Treatment of advanced malignancies with high-dose acetaminophen and N-acetylcysteine rescue. Cancer Invest 14, 202-210. (Pubitemid 26273556)
37. Jemnitz K, Veres Z, Monostory K, Kobori L, and Vereczkey L (2008). Interspecies differences in acetaminophen sensitivity of human, rat, and mouse primary hepatocytes. Toxicol In Vitro 22, 961-967.
38. Akai S, Hosomi H, Minami K, Tsuneyama K, Katoh M, Nakajima M, and Yokoi T (2007). Knock down of gamma-glutamylcysteine synthetase in rat causes acetaminophen-induced hepatotoxicity. J Biol Chem 282, 23996-24003. (Pubitemid 47328017)